Merck & Co. Inc. has decided that it will not commercialize its own version of Sanofi's Lantus (insulin glargine) in the US, even though the product was already tentatively approved by the US FDA in 2017.
"After a comprehensive assessment of the current and future market environment for insulin glargine, which included an assessment of anticipated...






